Comments on: It’s Official: IPOs and M&As Plummeted in First Quarter—New England Exits Hard to Find http://www.xconomy.com/boston/2008/04/01/its-official-ipos-and-mas-plummeted-in-first-quarter-new-england-exits-hard-to-find/ Business + Technology in the Exponential Economy Sun, 22 Nov 2009 16:55:51 -0600 http://wordpress.org/?v=2.8.6 hourly 1 By: Robert Buderi http://www.xconomy.com/boston/2008/04/01/its-official-ipos-and-mas-plummeted-in-first-quarter-new-england-exits-hard-to-find/comment-page-1/#comment-10912 Robert Buderi Tue, 01 Apr 2008 19:50:48 +0000 http://www.xconomy.com/2008/04/01/its-official-ipos-and-mas-plummeted-in-first-quarter-new-england-exits-hard-to-find/#comment-10912 This was the information from NVCA. We are checking it out. Thanks much Mark...Update...It looks like Mark is correct, and the NVCA just informed us they were removing it from the list. This was the information from NVCA. We are checking it out. Thanks much Mark…Update…It looks like Mark is correct, and the NVCA just informed us they were removing it from the list.

]]> By: Mark Milton http://www.xconomy.com/boston/2008/04/01/its-official-ipos-and-mas-plummeted-in-first-quarter-new-england-exits-hard-to-find/comment-page-1/#comment-10908 Mark Milton Tue, 01 Apr 2008 19:19:39 +0000 http://www.xconomy.com/2008/04/01/its-official-ipos-and-mas-plummeted-in-first-quarter-new-england-exits-hard-to-find/#comment-10908 I don't think that Acceleron were bought by Celgene for $12M but they did do a deal to related the development of certain products. Under the terms of the agreement, Celgene and Acceleron will jointly develop, manufacture and commercialize Acceleron’s products for bone loss. Celgene will make an upfront payment to Acceleron of $50 million, which includes a $5 million equity investment in Acceleron. In addition, in the event of an initial public offering of Acceleron, Celgene will purchase a minimum of $7 million of Acceleron common stock. I don’t think that Acceleron were bought by Celgene for $12M but they did do a deal to related the development of certain products.

Under the terms of the agreement, Celgene and Acceleron will jointly develop, manufacture and commercialize Acceleron’s products for bone loss. Celgene will make an upfront payment to Acceleron of $50 million, which includes a $5 million equity investment in Acceleron. In addition, in the event of an initial public offering of Acceleron, Celgene will purchase a minimum of $7 million of Acceleron common stock.

]]>